$ADAP
Adaptimmune Therapeutics PLC

2021 Q3 Form 10-Q Financial Statement

#000155837021010980 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $1.203M $3.095M $502.0K
YoY Change 0.84% 516.53% 219.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.17M $13.54M $10.30M
YoY Change 16.72% 31.45% 1.48%
% of Gross Profit
Research & Development $28.21M $28.87M $20.46M
YoY Change 17.22% 41.09% -19.8%
% of Gross Profit
Depreciation & Amortization $1.454M $1.439M $2.150M
YoY Change -20.55% -33.07% 9.14%
% of Gross Profit
Operating Expenses $28.21M $28.87M $20.46M
YoY Change 17.22% 41.09% -19.8%
Operating Profit -$42.18M -$39.31M -$30.25M
YoY Change 17.58% 29.94% -14.79%
Interest Expense $225.0K $266.0K $970.0K
YoY Change -89.53% -72.58% -117.54%
% of Operating Profit
Other Income/Expense, Net -$237.0K $54.00K -$749.0K
YoY Change -85.97% -107.21% -88.07%
Pretax Income -$42.19M -$38.99M -$29.86M
YoY Change 19.13% 30.6% -27.22%
Income Tax $208.0K $76.00K $25.00K
% Of Pretax Income
Net Earnings -$42.40M -$39.07M -$29.88M
YoY Change 19.67% 30.75% -27.28%
Net Earnings / Revenue -3524.61% -1262.29% -5952.19%
Basic Earnings Per Share -$0.05 -$0.04
Diluted Earnings Per Share -$45.27K -$0.04 -$36.32K
COMMON SHARES
Basic Shares Outstanding 936.5M 934.2M 780.6M
Diluted Shares Outstanding 936.6M 934.2M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.1M $285.4M $419.0M
YoY Change -39.96% -31.89% 214.07%
Cash & Equivalents $42.92M $50.45M $122.4M
Short-Term Investments $197.2M $234.9M $296.6M
Other Short-Term Assets $3.988M $1.309M $2.929M
YoY Change 49.81% -55.31% 388.98%
Inventory
Prepaid Expenses $9.970M $9.161M $7.903M
Receivables $1.641M $2.158M
Other Receivables $43.45M $37.75M
Total Short-Term Assets $300.5M $337.3M $458.1M
YoY Change -29.59% -26.36% 161.57%
LONG-TERM ASSETS
Property, Plant & Equipment $28.69M $28.66M $27.02M
YoY Change 6.48% 6.08% -19.87%
Goodwill
YoY Change
Intangibles $1.191M $1.382M $2.134M
YoY Change -39.54% -35.24% 3.29%
Long-Term Investments
YoY Change
Other Assets $1.717M $4.632M $6.100M
YoY Change -62.67% -24.07% -14.08%
Total Long-Term Assets $53.08M $52.45M $54.11M
YoY Change 1.51% -3.08% -15.96%
TOTAL ASSETS
Total Short-Term Assets $300.5M $337.3M $458.1M
Total Long-Term Assets $53.08M $52.45M $54.11M
Total Assets $353.5M $389.8M $512.2M
YoY Change -26.2% -23.9% 113.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.784M $6.977M $8.766M
YoY Change 18.71% -20.41% 101.8%
Accrued Expenses $27.98M $26.61M $23.84M
YoY Change 13.69% 11.62% 28.18%
Deferred Revenue $6.102M $4.911M $3.464M
YoY Change 67.87% 41.77% 14.85%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.14M $41.42M $38.56M
YoY Change 17.87% 7.41% 36.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $664.0K $667.0K $592.0K
YoY Change 7.97% 12.67% 3.68%
Total Long-Term Liabilities $664.0K $667.0K $592.0K
YoY Change 7.97% 12.67% 3.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.14M $41.42M $38.56M
Total Long-Term Liabilities $664.0K $667.0K $592.0K
Total Liabilities $112.5M $111.9M $104.6M
YoY Change 9.46% 6.92% 99.15%
SHAREHOLDERS EQUITY
Retained Earnings -$705.0M -$662.6M -$513.7M
YoY Change 28.39% 28.98% 32.74%
Common Stock $1.337M $1.336M $1.324M
YoY Change 0.91% 0.91% 40.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $241.0M $277.9M $407.6M
YoY Change
Total Liabilities & Shareholders Equity $353.5M $389.8M $512.2M
YoY Change -26.2% -23.9% 113.84%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$42.40M -$39.07M -$29.88M
YoY Change 19.67% 30.75% -27.28%
Depreciation, Depletion And Amortization $1.454M $1.439M $2.150M
YoY Change -20.55% -33.07% 9.14%
Cash From Operating Activities -$45.20M -$31.46M -$24.92M
YoY Change 176.96% 26.24% -27.07%
INVESTING ACTIVITIES
Capital Expenditures -$1.672M -$1.777M -$530.0K
YoY Change 109.0% 235.28% -47.52%
Acquisitions
YoY Change
Other Investing Activities $36.52M $49.46M -$186.5M
YoY Change -236.43% -126.52% -1052.94%
Cash From Investing Activities $34.85M $47.68M -$187.0M
YoY Change -226.36% -125.5% -1107.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 139.0K 2.567M 248.0M
YoY Change -70.43% -98.97% 75057.58%
NET CHANGE
Cash From Operating Activities -45.20M -31.46M -24.92M
Cash From Investing Activities 34.85M 47.68M -187.0M
Cash From Financing Activities 139.0K 2.567M 248.0M
Net Change In Cash -10.21M 18.79M 36.10M
YoY Change -76.49% -47.96% -336.26%
FREE CASH FLOW
Cash From Operating Activities -$45.20M -$31.46M -$24.92M
Capital Expenditures -$1.672M -$1.777M -$530.0K
Free Cash Flow -$43.53M -$29.68M -$24.39M
YoY Change 180.46% 21.7% -26.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
936237126
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001621227
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
936530694
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50453000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
928754958
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37368
dei Entity Registrant Name
EntityRegistrantName
ADAPTIMMUNE THERAPEUTICS PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
60 Jubilee Avenue, Milton Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Abingdon, Oxfordshire
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX14 4RX
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
44
dei Local Phone Number
LocalPhoneNumber
1235 430000
dei Security12b Title
Security12bTitle
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
dei Trading Symbol
TradingSymbol
ADAP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56882000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
234917000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
311335000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2158000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
139000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
49816000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29796000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
337344000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
398152000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4632000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4602000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17772000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18880000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34360000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31097000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28663000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27778000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1382000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1730000
CY2021Q2 us-gaap Assets
Assets
389793000
CY2020Q4 us-gaap Assets
Assets
451142000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6977000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6389000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2922000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2773000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26606000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27079000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4911000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2832000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
41416000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39073000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19723000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20938000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
50048000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
49260000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
667000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
644000
CY2021Q2 us-gaap Liabilities
Liabilities
111854000
CY2020Q4 us-gaap Liabilities
Liabilities
109915000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1240853520
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
936237126
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1038249630
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
928754958
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1336000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1325000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
949575000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
935706000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10385000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10048000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-662587000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585756000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
277939000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
341227000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
389793000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
451142000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3095000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
502000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3529000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1263000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28868000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20460000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53374000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41724000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13539000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10295000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27356000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19556000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
42407000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
30755000
us-gaap Costs And Expenses
CostsAndExpenses
80730000
us-gaap Costs And Expenses
CostsAndExpenses
61280000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-39312000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30253000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77201000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60017000
CY2021Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
266000
CY2020Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1147000
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
691000
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1877000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-749000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38992000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29855000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76457000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57952000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
374000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39068000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
us-gaap Net Income Loss
NetIncomeLoss
-76831000
us-gaap Net Income Loss
NetIncomeLoss
-58047000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
934228095
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
822725556
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
932667125
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
781235457
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39068000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
us-gaap Net Income Loss
NetIncomeLoss
-76831000
us-gaap Net Income Loss
NetIncomeLoss
-58047000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4177000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1194000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7178000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
19105000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
699000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3911000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1108000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6959000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20759000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-118000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
113000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39229000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29095000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77168000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59588000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
341227000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37763000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-176000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
535000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5334000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
309157000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39068000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-161000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000
CY2021Q2 adap Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
2519000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5449000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
277939000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-28167000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2326000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
894000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
90550000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1448000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
186037000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
785000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4181000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243838000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2624000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
407585000
us-gaap Profit Loss
ProfitLoss
-76831000
us-gaap Profit Loss
ProfitLoss
-58047000
us-gaap Depreciation
Depreciation
2879000
us-gaap Depreciation
Depreciation
3583000
us-gaap Share Based Compensation
ShareBasedCompensation
10783000
us-gaap Share Based Compensation
ShareBasedCompensation
4072000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77999000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8058000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3097000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339463000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
267000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2004000
adap Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
2884000
adap Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
702000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1401000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
480000
adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
21457000
adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
10104000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-615000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
663000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
3571000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1946000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
49074000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2924000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
460000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
143000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
407000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
154465000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
39931000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
81958000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
298016000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69440000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-258952000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2519000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
334388000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
578000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5075000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-937000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-678000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6399000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71775000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61484000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55085000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126683000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s </span>proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$662,587,000 as of June 30, 2021.</p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-662587000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3095000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
502000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3529000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1263000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)          Use of estimates in interim financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to valuation allowances relating to deferred tax assets, revenue recognition, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
adap Number Of Contracts With Customer
NumberOfContractsWithCustomer
2
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2126000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
211000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
47000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26606000
CY2021Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
37755000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
20585000
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9161000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2021Q2 adap Clinical Materials Current
ClinicalMaterialsCurrent
1591000
CY2020Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
2086000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1309000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
811000
CY2021Q2 adap Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
49816000
CY2020Q4 adap Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
29796000
CY2021Q2 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
14071000
CY2020Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
13081000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8474000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11825000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3850000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27079000
adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.71
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5449000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2624000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10783000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4072000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
918048
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2738936
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
15721104
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12968216
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.65
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2021Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
1995456
CY2020Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
778120
adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
14659248
adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
6838816
CY2021Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.88
CY2020Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.43
adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
1.01
adap Stock Issued Sales Agreement Remaining Amount Available For Sale
StockIssuedSalesAgreementRemainingAmountAvailableForSale
197359541

Files In Submission

Name View Source Status
0001558370-21-010980-index-headers.html Edgar Link pending
0001558370-21-010980-index.html Edgar Link pending
0001558370-21-010980.txt Edgar Link pending
0001558370-21-010980-xbrl.zip Edgar Link pending
adap-20210630.xsd Edgar Link pending
adap-20210630x10q.htm Edgar Link pending
adap-20210630x10q_htm.xml Edgar Link completed
adap-20210630xex31d1.htm Edgar Link pending
adap-20210630xex31d2.htm Edgar Link pending
adap-20210630xex32d1.htm Edgar Link pending
adap-20210630xex32d2.htm Edgar Link pending
adap-20210630_cal.xml Edgar Link unprocessable
adap-20210630_def.xml Edgar Link unprocessable
adap-20210630_lab.xml Edgar Link unprocessable
adap-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending